Aptevo Therapeutics Inc. — Director's Dealing 2018

Aug 11, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2018-08-01

Reporting Person: Mitchell Shawnte (SVP, GC and Corporate Affairs)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	74505	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$1.63	2020-08-07	Common Stock (2650)		Direct
Employee Stock Option (Right to Buy)	$2.47	2021-03-10	Common Stock (35267)		Direct
Employee Stock Option (Right to Buy)	$2.55	2022-03-09	Common Stock (28441)		Direct
Employee Stock Option (Right to Buy)	$3.03	2022-08-09	Common Stock (9783)		Direct
Restricted Stock Unit	$	2018-08-09	Common Stock (1630)		Direct
Employee Stock Option (Right to Buy)	$2.97	2026-02-28	Common Stock (40614)		Direct
Restricted Stock Unit	$	2019-03-01	Common Stock (6787)		Direct
Employee Stock Option (Right to Buy)	$1.96	2027-02-23	Common Stock (17500)		Direct
Employee Stock Option (Right to Buy)	$2.15	2027-06-30	Common Stock (17500)		Direct
Employee Stock Option (Right to Buy)	$3.13	2028-03-09	Common Stock (35000)		Direct

Footnotes

F1: Each security was originally issued by Emergent BioSolutions Inc. and, as a result of the spin-off of the Issuer from Emergent BioSolutions Inc. effective on August 1, 2016, was adjusted and assumed by the Issuer, other than 41,497 shares of the Issuer's common stock that was issued in connection with the spin-off.

F2: The stock option was granted on August 8, 2013 and became exercisable in three equal annual installments beginning on August 7, 2014.

F3: The stock option was granted on March 11, 2014 and became exercisable in three equal annual installments beginning on March 10, 2015.

F4: The stock option was granted on March 10, 2015 and became exercisable in three equal annual installments beginning on March 9, 2016.

F5: The stock option was granted on August 10, 2015. 3,261 shares underlying the stock option became exercisable on each of August 9, 2016 and August 9, 2017, and the remaining 3,261 shares become exercisable on August 9, 2018.

F6: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F7: On August 10, 2015 the reporting person was granted 4,892 restricted stock units. 1,631 shares of common stock underlying the restricted stock units vested on each of August 9, 2016 and August 9, 2017, and the remaining 1,630 shares vest on August 9, 2018.

F8: The stock option was granted on March 1, 2016. 13,538 shares underlying the stock option became exercisable on each of February 28, 2017 and February 28, 2018, and the remaining 13,538 shares become exercisable on February 28, 2019.

F9: On March 1, 2016 the reporting person was granted 20,365 restricted stock units. 6,789 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 6,787 shares vest on March 1, 2019.

F10: The stock option was granted on February 24, 2017. 5,833 shares underlying the stock option became exercisable on February 23, 2018, 5,833 shares become exercisable on February 23, 2019 and 5,834 shares become exercisable on February 23, 2020.

F11: The stock option was granted on June 1, 2017. 5,833 shares underlying the stock option became exercisable on May 31, 2018, 5,833 shares become exercisable on May 31, 2019 and 5,834 shares become exercisable on May 31, 2020.

F12: The stock option was granted on March 10, 2018 and becomes exercisable in three equal annual installments beginning on March 9, 2019.